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cytes has been associated with CR in a mouse model (31, 32) and in patients (13, 39, 41, 47) . Furthermore, numerous TGF-␤-inducing factors, such as angiotensin II, endothelin-1, ischemia, and cyclosporine (CsA) (7) , are also related to CR development in kidney transplants (10, 55) . TGF-␤ induces extracellular matrix (ECM) production and/or inhibits its degradation (7) and is a key factor for epithelial-mesenchymal transition (EMT) in the transformation of renal TECs into myofibroblasts (30, 44, 45, 47, 49, 53, 56) . All this evidence suggests that TGF-␤ might contribute to CR and has been suggested as a key target for treating CR (30) .
An anti-TGF-␤ monoclonal antibody (1D11) neutralizes the biological activity of both TGF-␤1 and ␤2 (15) , and its therapeutic potential for treating kidney disease has been tested in many experimental models; it has been demonstrated to have antihypertensive and antiproteinuric effects and to protect renal tissues from injury or fibrosis in Dahl salt-sensitive (Dahl S) rats (14) , diabetic rats (5, 6) , uremic rats (26) , and rats that underwent unilateral ureteral obstruction (UUO) (18, 35) or with puromycin aminonucleoside nephropathy (29) . It also protects the kidney from chronic CsA nephropathy in mice (28) . Moreover, treatment with this antibody prevents radiation-induced lung injury by decreasing morphological changes and the inflammatory response in rats (2) . In this study, the efficacy of this antibody in the prevention of CR of renal allografts was tested in a rat model.
MATERIALS AND METHODS

Animals and drugs.
Male rats (Fischer 344 and Lewis) were purchased from Charles River Laboratories (Wilmington, MA) and maintained in the animal facility of the Jack Bell Research Centre of the University of British Columbia (Vancouver, British Columbia, Canada). Animal experiments were performed in accordance with the Canadian Council on Animal Care guidelines under protocols approved by the Animal Use Subcommittee at the University of British Columbia.
Both anti-TGF-␤ (clone 11D1) and control anti-verotoxin (clone 13C4) antibodies were kindly provided by Genzyme/Sanofi (Cambridge, MA). CsA (Sandimmune* Immunosuppressant) was purchased from Novartis Pharmaceuticals Canada (Dorval, QC, Canada).
Kidney transplantation and antibody treatments. Kidney transplantation was performed following a standard procedure as described previously (24) , in which male Lewis rats (RT1 1 ) were used as recipients and male Fischer 344 rats (RT1 1v1 ) as donors (Allograft group). Isografts were done between Lewis rats as controls for alloimmune-mediated CR in renal allografts. In brief, a donor rat was anesthetized with a mixture of ketamine and isoflurane, its left kidney was flushed in situ with saline, and then it was harvested as a donor kidney. Following a short period of preservation (Ͻ20 min) in saline on ice, the donor kidney was transplanted orthotopically into a recipient rat under isoflurane anesthesia, in which native left kidney was removed after left renal vessels were dissected free and clamped. The left renal vessels and ureter were anastomosed end-to-end using 10-0 prolene sutures. Vascular clamps were released immediately after the vascular anastomoses were completed, with a warm ischemic time of Ͻ30 min. CsA (5 mg·kg Ϫ1 ·day Ϫ1 ) was administered daily subcutaneously to all recipient rats for 10 days immediately after transplantation, and the native right kidney in the recipients was removed on day 7 posttransplantation. Recipient rats were excluded from the studies if surgical or urological complications were observed during the period of CsA treatment.
Rats receiving renal allografts were randomly separated into two groups that were treated with two different antibodies: an anti-TGF-␤ antibody (clone 11D11, 5 mg/kg) based on previous studies in rats (14, 18, 29) and the same amount of a control anti-verotoxin antibody (clone 13C4). Both antibodies were administrated by intraperitoneal injection at a given dose three times a week (Monday, Wednesday, and Friday), starting from week 8 after transplantation to week 20. The beginning of antibody treatment was planned based on the previous studies showing that the pathological changes for CR in this preclinical model have been seen at week 12 (3) .
Urine collection and proteinuria determination. The 24-h urine sample was collected from each recipient rat that was kept in a metabolic cage with access to food and drinking water for 24 h, followed by centrifugation at 3,000 rpm for 10 min to remove any cells and other debris from urine. The final urine samples were stored at Ϫ80°C until further use. The protein concentration in urine was measured using a Bio-Rad Bradford protein assay following trichloroacetic acid (TCA) precipitation, and the amount of precipitated protein was calculated compared with bovine serum albumin (BSA) standards.
Histopathological determination of graft rejection. Grafts at the end of antibody treatment were perfused with saline. A coronal tissue slice through the midportion of each graft was fixed in 10% neutral buffered formalin, followed by embedding in paraffin wax. Sections were cut at 4-m thickness and stained with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS), or Masson's trichrome method. The pathological parameters of CR were determined under microscopic view (ϫ200 magnification) in two separate sections of each graft in a blinded fashion as described previously (23, 48) .
The extent of mononuclear cell infiltration in the renal cortex of a graft was assessed in H&E-stained sections using a 0 -4 scale, depending on the percentage of cellular infiltrate-occupied area in each microscopic view: 0 (normal or no sign of infiltration), 1 (1-10% of the area affected with cellular infiltration), 2 (11-25%), 3 (26 -50%), and 4 (Ͼ50%). The average of at least 20 randomly selected views represented the infiltration in each graft.
The number of injured tubules, including cellular loss (atrophy), intratubular cast formation, tubular cell flattening or vacuolation, in each microscopic view in the renal cortex of a graft was counted in PAS-stained section, and the average number of at least 20 randomly selected views represented the injured tubules in each graft.
The degree of tubulointerstitial fibrosis in the renal cortex of a graft, and the percentage of affected glomeruli (glomerulopathy) and interlobular arterioles or arteries, were determined in Masson's trichrome-stained sections; tubulointerstitial fibrosis was determined using a 0 -4 scale based on the severity of tubular dilation or the percentage of the area stained positively with collagen fibers: 0 (normal interstitium with the absence of collagen fiber stain), 1 (minimal collagen fiber stain or Ͻ5% of affected area), 2 (mild or 6 -25%), 3 (moderate or 26 -50%), and 4 (severe, or affecting Ͼ50% of the cortical area). The percentage of affected glomeruli (glomerulopathy), including glomerulosclerosis (focal and segmental sclerosis) and glomerular hypertrophy, was determined in a range of 45-130 glomeruli for each graft. In addition, the percentage of affected interlobular arterioles or arteries, determined by the presence of fibrous intima, was counted in a range of 10 -30 interlobular arteries or arterioles of each graft.
Immunohistochemical analysis. The number of infiltrating macrophages (MØ), T cells, CD4-, and CD8-positive T cells in the sections of renal allografts was semiquantitatively assessed by an immunohistochemical method. In brief, after deparaffinization and rehydration, the antigen retrieval in tissue sections was performed by boiling the slides in citrate buffer (pH 6.0) for 30 min. After blocking with 5% normal rabbit serum, the tissue sections were incubated with a 1:50 dilution of a mouse monoclonal MØ marker antibody (Clone MAC387, Santa Cruz Biotechnology, Dallas, TX), pan T cell marker antibody (Clone 6A624, Santa Cruz Biotechnology), CD4 antibody Control, grafts from recipients treated with control antibody (clone 13C4); anti-transforming growth factor (TGF)-␤, grafts from those treated with anti-TGF-␤ antibody (clone 11D1). The tissue sections of 4 grafts were randomly selected from each group for the immunohistochemical analysis of MØs, T cells, CD4, and CD8 cells. The score of infiltration for the graft was derived from (Clone W3/25, Santa Cruz Biotech), or CD8-␣ antibody (Clone OX8) overnight at 4°C. The immune complex of targeted antigen/antibody on the tissue section was detected using horse anti-anti-mouse IgG antibody conjugated with biotin (1:1,000 dilution, Vector Labs, Burlington, ON), which was visualized with the 3,3=-diaminobenzidine (DAB) peroxidase substrate kit (Vector Labs). Negative controls for staining were the sections stained with normal mouse IgG as the first antibody or without this antibody. The positively stained cells in each randomly selected view of graft cortex were counted under ϫ400 magnification (high-power field; hpf) in a blinded fashion, and the average of cell count per hpf from at least 20 -30 nonoverlapping views was used to represent the number of each type of infiltrating leukocyte for each graft.
PCR array. The expression of a panel of cytokine genes and fibrosisassociated genes was quantitatively examined using PCR array kits the following manufacturer's instructions (SABiosciences-Qiagen, Valencia, CA). In brief, following perfusion with saline, one part of the graft tissue was snap-frozen in liquid nitrogen and stored at Ϫ80°C. Four grafts from each group were randomly selected for the determination of a gene expression profile using PCR arrays. The total RNA from graft tissues was extracted and purified using the RNeasy Microarray Tissue Mini kit (Qiagen) and converted to cDNA using an RT 2 First Strand Kit (Qiagen). The expression of selected genes was amplified by real-time PCR using RT 2 Profile PCR arrays (Qiagen). Data were analyzed using Web-based PCR Array Data Analysis Software (www.SABiosciences.com/ pcrarraydataanalysis.php.).
Determination of graft function. Serum samples from recipient rats were collected at the end of antibody treatment (week 20 posttransplantation) using cardiac puncture method and stored at Ϫ80°C. Graft function was determined by both the levels of serum creatinine and blood urea nitrogen (BUN) and by creatinine clearance. The creatinine concentrations were measured using a Creatinine Assay kit (BioVision, Mountain View, CA), while BUN was determined with a Quantichrom Urea Assay kit (BioAssay Systems, Hayward, CA) following the manufacturer's protocol.
Creatinine clearance or the glomerular filtration rate (GFR) of kidney transplants was calculated by the formula as follows: GFR ϭ [UCr ϫ V]/SCr, where UCr represents the creatinine concentration in a 24-h urine sample, V was the volume (ml) of the 24-h urine sample, and SCr was the creatinine level in the serum from the same recipient animal.
Statistical analysis. The data are presented as means Ϯ SE for each group. Statistical analysis of group differences was performed by Student's t-test or ANOVA as appropriate. A P value Յ0.05 is considered to be statistical significance.
RESULTS
Protecting glomerular function by anti-TGF-␤ antibody treatment.
The CR of renal allografts has been well established in a rat model: the donor kidneys from male Fischer 344 rats are transplanted into male Lewis rats (33) . The levels of total proteins in 24-h urine samples (proteinuria) from recipient rats were measured as a marker of transplant glomerular dysfunction. The urinary protein excretion in the anti-TGF-␤ antibodytreated group was slightly increased following the time of antibody treatment but was significantly less than that in control antibody-treated group (Fig. 1 ). This is indicated by 48.39 Ϯ 1.32 mg at week 10 posttransplantation (or 2 wk post-antibody treatment) to 82.59 Ϯ 3.36 mg at week 20 in the anti-TGF-␤ antibody-treated group, compared with 78.0 Ϯ 1.62 mg to 189.83 Ϯ 19.39 mg at the same period of time in the control antibody-treated group (P ϭ 0.0002, two-way ANOVA, n ϭ 10). In the recipients receiving renal isografts, the range of the protein level in 24-h urine samples was from 25 to 65 mg at the end point of the experiment (n ϭ 3).
Reducing intragraft cellular inflammation by anti-TGF-␤ antibody treatment. The persistent or chronic immune response is one of the key risk factors for CR of kidney allografts (19, 38) . To examine the effect of anti-TGF-␤ antibody treatment on the severity of cellular inflammation in the interstitium of renal allografts, the mononuclear infiltrate-affected areas in H&E-stained sections of grafts were examined. As shown in Fig. 2 , less inflammatory infiltration was seen in the grafts from anti-TGF-␤ antibody-treated recipients compared with those in the control group, indicated by the lower scores of the cellular infiltration (0.713 Ϯ 0.12) in the anti-TGF-␤ antibody-treated group compared with those (1.592 Ϯ 0.359) in the control Control, grafts from recipients treated with control antibody (clone 13C4); anti-TGF-␤, grafts from those treated with anti-TGF-␤ antibody (clone 11D1). n, No. of determinants; EMT, epithelial-to-mesenchymal transition; ECM, extracellular matrix. group (P ϭ 0.0282, Student's t-test, n ϭ 10), while only a minimal level of cellular infiltration was observed in those isografts (data not shown). These data suggest that the beneficial effect of anti-TGF-␤ antibody therapy on reducing the CR of renal allografts is associated with the reduction of intragraft cellular inflammation or infiltration.
To determine whether the types of infiltrating leukocytes that were associated with CR of renal allografts were attenuated by anti-TGF-␤ antibody treatment, the numbers of infiltrating MØs, T cells, and CD4 and CD8 T cells were counted in the graft sections stained with MØ marker, pan T cell marker, and CD4 or CD8-␣ antibodies, respectively. Overall, the number of each type of infiltrating leukocytes was positively correlated with the severity of cellular infiltration in both groups as expected (Table 1) , and the ratios of MØ to T cells or CD4 to CD8 were not statistically different between the control antibody-treated and anti-TGF-␤ antibody-treated groups in this limited number of samples. However, it was clearly seen that in those grafts with more severity of cellular infiltration (i.e., score Ͼ1.0), more MØs were found as indicated by the higher ratios of MØs to T cells (Table 1) , and these MØs were mostly localized in the boundary between renal tissues and infiltrate "nodules" (Fig. 3) .
To further reveal the CR-associated phenotypes of intragraft inflammation, and to examine whether the phenotypes were affected by anti-TGF-␤ antibody treatment, the intragraft expression profile of the most abundant leukocyte-producing cytokines was examined in control antibody-treated allografts vs. isografts and in anti-TGF-␤ antibody-treated allografts vs. control antibody-treated allografts. PCR array data showed that six leukocyte-producing cytokines (lymphotoxin ␣, IL-2, IL-1␣, CSF2, IFN-␥, and IL-21) were upregulated by Ͼ20-fold in control antibody-treated allografts compared with those in isografts ( Table 2 ), indicating that the most of these leukocyte infiltrates in renal allografts with CR are likely T cells (CD4 ϩ Th1, Th2, Th17, and NK T cells) and monocytes/MØs. Compared with control antibody-treated allografts, the expression of IL-1␣ and IFN-␥, as well as IL-4 and IL-5 (Table 3) , was significantly decreased in anti-TGF-␤ antibody-treated allo- grafts, suggesting that anti-TGF-␤ antibody treatment attenuates the infiltration of all of Th1, Th2, and monocytes/MØs in renal allografts, which is indeed in line with the results of the immunohistochemical analysis (Table 1) .
Reducing renal tubular injury by anti-TGF-␤ antibody treatment.
One of the consequences of cellular inflammation or infiltration could be presented by cell death or injury in a kidney transplant. In PAS-stained sections of renal grafts, renal tubular injury was identified as renal tubular atrophy, intratubular cast formation, tubular cell flattening, or vacuolation (Fig. 4A) . Renal tubular atrophy was indicated by cellular loss and basement membrane thickening or disruption and was mostly associated with cellular infiltration (Fig. 4A) . A semiquantitative analysis indicated that the number of injured tubules was significantly reduced by anti-TGF-␤ antibody treatment, indicated by the average of 3.164 Ϯ 1.132 damaged tubules/microscopic view in the anti-TGF-␤ antibody-treated group, significantly less than 7.396 Ϯ 1.448 in the control group (P ϭ 0.0334, Student's t-test, n ϭ 10). Taken together, the protective effect of anti-TGF-␤ antibody treatment in this kidney transplantation model was associated with its reduction of cellular inflammation and renal tubular damage.
Preventing renal tissue fibrosis by anti-TGF-␤ antibody treatment. Tissue fibrosis in kidney transplants, a histological hallmark of CR, is characterized by a progressive process of excess ECM deposition in the interstitium (interstitial fibrosis), glomeruli (glomerulosclerosis), and arterial wall (vascular sclerosis) (37, 43, 54) . The distribution of collagen fibers, a major or the most abundant structural protein of ECM, in graft sections was examined with Masson's trichrome stain. As shown in Fig. 5A , the blue-stained collagen fibers were located in the pervascular area and arterial wall, tubulointerstitium, glomerular capillary walls, and mesan- gium. In addition, the levels of collagen fiber deposition in the grafts from the anti-TGF-␤ antibody-treated group were lower than those in the control group. Histological scoring of the collagen fiber deposition in each type of renal tissue indicated that anti-TGF-␤ antibody treatment significantly reduced the collagen fiber deposition in kidney grafts, reflected by the lower scores of interstitial fibrosis (0.853 Ϯ 0.158) in the anti-TGF-␤ antibodytreated group compared with that (1.893 Ϯ 0.326) in the control group (P ϭ 0.0113, Student's t-test, n ϭ 10) (Fig. 5B) , and the lower percentages of the affected glomeruli (52.578 Ϯ 10.331%) in the anti-TGF-␤ antibody-treated group compared with that (85.915 Ϯ 4.997%) in the control group (P ϭ 0.0105, Student's t-test, n ϭ 10) (Fig. 5C) , or of the affected interlobular arterioles or arteries (19.079 Ϯ 7.923%) in the anti-TGF-␤ antibody-treated group compared with that (71.071 Ϯ 10.684%) in the control group (P ϭ 0.0016, Student's t-test, n ϭ 10) (Fig. 5D) .
The histological evidence of reducing tissue fibrosis in kidney transplants by anti-TGF-␤ antibody therapy was supported by PCR array data. As listed in Table 3 , the severity of graft fibrosis in the control antibody-treated group was associated with a significant increase in the expression of collagen type I and III and of profibrotic factors or regulators (TGF-␤1, CCL12, IL-13, IL-4, IL-5, and Snail), and as well with a significant decrease in the expression of antifibrotic molecules (BMP3-7, HGF). Following the treatment with the anti-TGF-␤ antibody, the expression of profibrotic genes, including TGF-␤1, TGF-␤2 (but not TGF-␤3), CCL2, IL-13, IL-4, and IL-5, were significantly reduced, and of collagen type I and III and Snail to a lesser extent but not statistically significant in this limited number of determinants (n ϭ 4 or 8), while the antifibrotic HGF, BMP5, and BMP7 were upregulated (Table 3) .
Maintaining graft function by anti-TGF-␤ antibody treatment. To further confirm the histological evidence for a beneficial effect of anti-TGF-␤ antibody treatment on preventing CR of kidney transplants, the graft function in the anti-TGF-␤ antibody-treated group vs. the control group was determined by measuring serum creatinine and BUN and creatinine clearance at the end of the antibody treatment. As indicated in Fig. 6 , anti-TGF-␤ antibody treatment prevented the loss of graft function, indicated by the lower levels of serum creatinine (0.961 Ϯ 0.018 mg/dl) in anti-TGF-␤ antibody-treated recipients compared with that (1.309 Ϯ 0.054) in control antibodytreated recipients (P ϭ 0.031, Student's t-test, n ϭ 10) (Fig.   6A ), or of BUN (63.364 Ϯ 1.425 mg/dl) in anti-TGF-␤ antibody-treated recipients compared with that (79.051 Ϯ 2.089 mg/dl) in control antibody-treated recipients (P ϭ 0.0149, Student's t-test, n ϭ 10) (Fig. 6B) . As shown in Fig. 6C , the beneficial effect of anti-TGF-␤ antibody therapy on the preservation of renal transplant function was also supported by the measurement of creatinine clearance or GFR; the anti-TGF-␤-treated renal allografts had the higher creatinine clearance (596.70 Ϯ 72.11 ml) compared with those (390.96 Ϯ 29.86 ml) in the control group (P ϭ 0.01955, Student's t-test, n ϭ 8).
DISCUSSION
TGF-␤ has been proposed as a therapeutic target for preventing renal allograft fibrosis (16, 17, 30) . The present study for the first time demonstrates that neutralizing activities of both TGF-␤ isoforms (TGF-␤1 and TGF-␤2) using an anti-TGF-␤ antibody (11D1) successfully reduces the severity of CR of renal allografts in a rat model; compared with a control antibody (clone 13C4)-treated group, administration of anti-TGF-␤ monoclonal antibody (1D11) is associated with a significant reduction of proteinuria, serum creatinine, and BUN in kidney transplant recipients, or prevents creatinine clearance decline in kidney transplants. The efficacy of anti-TGF-␤ antibody therapy against the CR of renal allografts is further evidenced by its reduction of the severity of cellular infiltration, tubular injury, and graft tissue fibrosis, and the expression of its associated genes in renal allografts.
In biopsies of kidney transplants from patients, CR is presented in kidney transplants as early as 3 mo after transplantation (37) and has been characterized as a progressive process of interstitial fibrosis, tubular atrophy, glomerulosclerosis, and vascular sclerosis (37, 43, 54) . Although the pathogenesis of CR is not fully understood, it has been proposed that these pathologies may result from the endless repeating of both the immune-and non-immune-mediated insults (12, 34, 42) , implying that CR in kidney transplants starts from tissue injury, caused by both immune-and non-immune responses (i.e., chronic leukocyte and/or antibody-mediated rejection, and immunosuppressive drug nephrotoxicity), that then further recruits inflammatory infiltrates, particularly the MØs as the number of these cells is largely increased in those grafts with the severe cellular infiltration (Table 1) . Tissue injury concur- rently stimulates tissue repair/cell proliferation including EMT and myofibroblast activation. The cycle of tissue injury-repair could be repeated as long as the transplant is not removed. As a consequence, this chronic tissue injury-repair slowly but progressively induces tissue remodeling, including accumulation of ECM in functional tissue that results in successive tissue fibrosis; vascular sclerosis in the vascular system, interstitial fibrosis in the tubulointerstitium, and glomerulosclerosis in the glomeruli. The evidence of this study may support this hypothesis. First, histological examinations show that CR of kidney transplants is accompanied by severe leukocyte infiltration, and the beneficial effect of anti-TGF-␤ antibody therapy on reducing CR is closely correlated with less intragraft cellular infiltration, suggesting that the alloimmune-mediated tissue injury plays an important role in the development of CR of renal allografts in this model, which is consistent with PCR array data: leukocyte activation-associated cytokines are the most abundant upregulated genes (Ͼ20-fold increase) ( Table  2) , and proapoptotic TNF superfamily ligands (9 of 10 members) are notably increased in renal allografts with CR in the control antibody group compared with isografts (data not shown). Second, as indicated by PCR array analysis (Table 3) , tissue fibrosis of renal allografts is confirmed by the upregulation of collagen type I and III expression and is associated with upregulation of TGF-␤1 and CTGF (growth factors for ECM accumulation), CCL12 for fibrocyte recruitment (36) , and promotion of EMT that is indicated by the increase in Snail and MMP2 expression (8, 11) and the loss of BMP5, BMP7, and HGF, EMT inhibitors in the kidney (4, 9) .
It has been documented that the levels of intragraft TGF-␤1 and active plasma TGF-␤1 are positively correlated with CR in kidney transplants in patients (21, 39, 47) , and the present study demonstrates that the expression of TGF-␤1 (but not TGF-␤2 and TGF-␤3) in the renal allografts of the control antibody group compared with that in isografts is significantly upregulated, and neutralization of TGF-␤1 and TGF-␤2 using the anti-TGF-␤ antibody (clone 11D1) significantly decreases the expression of these two factors (but not TGF-␤3) ( Table 3) . How the inactivation of TGF-␤1 and TGF-␤2 reduces the severity of CR in kidney transplants is not completely understood as yet. It has been proposed that chronic injury in kidney transplants causes dysfunction of resident TECs, which triggers release of TGF-␤ and recruitment of inflammatory cells to injured kidneys (17) . In addition to lymphocytes and monocytes/MØs, kidney cells also produce TGF-␤ in response to the stimulation of proinflammatory/cell injury factors, such as interleukin-1␤ and TNF-␣ (20, 51) . TGF-␤ is a multifunctional factor that controls migration, proliferation, and differentiation of every leukocyte lineage (27) as well as promotes renal tissue fibrosis via the induction of EMT (22) , ECM production, and/or inhibition of ECM degradation in kidney cells (7, 51) . The data in this study clearly show that there are two consequences from the inactivation of TGF-␤ and TGF-␤2 by anti-TGF-␤ antibody treatment. One is to reduce interstitial cellular infiltration, such as MØs, T cells, and probably infiltrating fibrocytes, a circulating connective tissue cell progenitor that can contribute kidney fibrosis (52) , which is reflected by the downregulation of CCL12, proinflammatory cytokines (CSF2, IFN-␥, TNF-␣, IL-1, IL-4, IL-5, IL-13, IL-20, and IL-33), and transcription factor NF-B1 in anti-TGF-␤ antibody-treated kidney transplants vs. control antibody-treated transplants (data not shown). The other is to control the progression of tissue fibrosis, probably including EMT, indicated by the significant upregulation of antifibrotic HSF, BMP5, and BMP7 in anti-TGF-␤ antibody-treated kidney transplants (Table 2) . Taken together, all the evidence suggests that the treatment with the anti-TGF-␤ antibody (clone 11D1) neutralizes the biological activities of TGF-␤1 and TGF-␤2, resulting in inactivation of the molecular pathways for interstitial cellular infiltration, renal tissue damage, and fibrosis.
In conclusion, chronic kidney transplant rejection largely contributes to kidney transplant failure and becomes a major risk factor for the returning of kidney transplant recipients to dialysis. To date, there is no effective therapy for this problem. In addition to many previous experimental studies showing the beneficial effects of the anti-TGF-␤ antibody (1D11) in treating various types of chronic kidney diseases, our present study has demonstrated that administration of this type of anti-TGF-␤ antibody successfully reduces the severity of chronic kidney transplant rejection in a rat model, suggesting the therapeutic potential for neutralizing TGF-␤ activity using the anti-TGF-␤ antibody (1D11) and for preventing the CR of kidney transplants or prolonging kidney transplant survival in patients. 
